Table 2.
Background Characteristics of Subgroups Used for Ancillary Study Analysis
| Characteristic | IH (N=100) | CR (N=100) | PR (N=100) |
P value |
|||
|---|---|---|---|---|---|---|---|
| Overall | IH vs CR | IH vs PR | CR vs PR | ||||
| Age (y), median | 64.0 | 70.5 | 70.0 | <.001 | <.001 | <.001 | .34 |
| Indication for BM (%) | .04 | .08 | .02 | .60 | |||
| Cytopenia, r/o MDS | 13 | 16 | 24 | ||||
| Lymphoma or staging | 23 | 21 | 26 | ||||
| MDS | 7 | 7 | 10 | ||||
| MPN | 3 | 11 | 4 | ||||
| Acute leukemia | 6 | 5 | 4 | ||||
| Metastasis | 3 | 2 | 1 | ||||
| Cytosis, r/o MPN | 3 | 6 | 5 | ||||
| Plasma cell | 40 | 23 | 17 | ||||
| MDS/MPN | 2 | 8 | 8 | ||||
| Other | 0 | 1 | 1 | ||||
CR = clinically referred; IH = in-house; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasm; PR = pathologist referred; r/o = rule out.